Deal Details
FDS Is Acquired by Omnicell
Summary
FDS (the “Company”), a portfolio company of Calvert Street Capital Partners (“Calvert Street”), has been acquired by Omnicell (NASDAQ: OMCL) for $177 million.
Baird served as the exclusive financial advisor to FDS on this transaction.
About
FDS strengthens the health of pharmacies and their patients through the delivery of innovative software products and services that enable the evolution of the clinically focused New Era Pharmacy. The Company’s product suite includes comprehensive cloud-based financial, analytic and clinical care and population health solutions designed to serve all sizes of clients within the pharmacy ecosystem. The Company’s customer base comprises more than 15,500 pharmacies ranging from small independent community pharmacies to regional and national chains across all 50 states. FDS is headquartered in Fort Worth, Texas.Founded in 1995, Calvert Street is a lower middle market investment firm based in Baltimore, Maryland. Since its inception, Calvert Street has partnered with owner-operators and skilled management teams to support profitable growth and organizational transformations. Calvert Street has invested in over 120 companies representing cumulative transaction values in excess of $1.5 billion across industrial services, specialty manufacturing and tech-enabled industrial & business services.
Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Over 7,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence and improve patient safety. More than 50,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions.
CONTACT US TO LEARN MORE
- Date
- September 2021
- Company
- FDS
- Transaction
- M&A - Sellside
- Sectors
- Healthcare
- Verticals
-
Healthcare IT & Services
- Target Geography
- North America
- Acquiror Geography
- North America
Share